Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Dr. Bendell joined Sarah Cannon in 2008 and serves as Chief Development Officer. In her role, Dr. Bendell leads the development and expansion of physician, site and Pharma relationships across the Sarah Cannon network. Additionally, Dr. Bendell serves as Director of the GI Cancer Research Program, overseeing the clinical trial menu for GI cancers across the Sarah Cannon network. Her work in early drug development has helped guide first-in-man agents through proof-of-concept studies.
Dr. Bendell received her undergraduate and medical degrees from the University of Chicago in 1994 and 1998, respectively. She completed her internship and residency in the Department of Internal Medicine at Brigham and Women's Hospital in Boston, as well as a fellowship in adult oncology at Boston's Dana-Farber Cancer Institute. She is board certified in medical oncology. Additionally, she is an associate with Tennessee Oncology, PLLC.